CAN04 + carboplatin + pemetrexed

**CAN04 + carboplatin + pemetrexed** is an investigational combination regimen used for the treatment of solid tumors, notably non-squamous non-small cell lung cancer (NSCLC)[3][5]. - **CAN04 (nadunolimab)** is a first-in-class, fully humanized, ADCC-enhanced monoclonal antibody targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP)[3][5]. Its mechanisms include: blockade of intracellular signaling through IL1RAP, thereby reducing tumor-promoting cytokine secretion and inflammation; and induction of antibody-dependent cellular cytotoxicity (ADCC), stimulating natural killer (NK) cells to attack IL1RAP-expressing tumor cells[3][5]. - **Carboplatin** is a platinum-based chemotherapy agent that induces DNA crosslinking and apoptosis. - **Pemetrexed** is an antifolate chemotherapeutic that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), interfering with folate-dependent nucleotide synthesis critical for cell replication[2][4][6]. This combination has been studied in clinical trials for NSCLC in dose escalation and expansion cohorts as part of phase I/II trials[3][5][1].

Brand names

CAN04 (if considered as code name/brand for nadunolimab)

Other names

carboplatinpemetrexednadunolimab